Announcements Trials

Browse Landscape

Phase

Phase 1 6 Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 685 Breast Neoplasms 584 Neoplasms 468 Colorectal Neoplasms 298 Prostatic Neoplasms 262 Neoplasm Metastasis 256 Melanoma 241 Ovarian Neoplasms 228 Recurrence 216 Lung Neoplasms 203 Multiple Myeloma 195 Lymphoma, Non-Hodgkin 155 Pancreatic Neoplasms 154 Leukemia, Myeloid, Acute 141 Carcinoma, Hepatocellular 141 Stomach Neoplasms 137 Lymphoma 131 Carcinoma, Renal Cell 128 Glioblastoma 118 Head and Neck Neoplasms 112 Squamous Cell Carcinoma of Head and Neck 111 Lymphoma, Follicular 106 Leukemia, Lymphocytic, Chronic, B-Cell 99 Lymphoma, Large B-Cell, Diffuse 96 Leukemia 96 Small Cell Lung Carcinoma 95 Brain Neoplasms 91 Carcinoma 82 Uterine Cervical Neoplasms 76 Triple Negative Breast Neoplasms 72

Interventions

ridaforolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × INDUSTRY × Advanced Cancers × Clear all

NCT00836927 2019-02-18

MK-8669-038

Merck Sharp & Dohme LLC

Phase 2 Terminated

7 enrolled 13 charts

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡